Company intelligence / Profile preview

Bure Equity

Stockholm, Sweden

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Bure Equity is a Swedish investment company focused on long-term, active ownership in a diversified portfolio of knowledge-driven, innovation-based companies, primarily in the Nordics and European developed markets. Its portfolio includes significant holdings in medtech, biotech, healthcare, and life science companies, among others. Bure is not a biotech, pharma, or CRO itself, but an owner and developer of such companies, taking majority or controlling stakes and providing strategic guidance and capital[1][3][8].

Industry: Investors

Partnerships

Lauxera Capital Partners (BioLamina)Tryggvason family (BioLamina)Northislet (BioLamina)

Beyond the preview

Go deeper on Bure Equity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bure Equity.

Explore the full profile